Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23.
週五，艾伯維公司（紐約證券交易所代碼：ABBV）公佈的第一季度調整後每股收益爲2.31美元，同比下降6.1％，超過市場預期的2.23美元。
Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis.
淨收入達到123.1億美元，增長0.7％，超過了市場普遍預期的119.2億美元。銷售額在運營基礎上增長了1.6％。
"First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform," said Robert Michael, president and chief operating officer.
總裁兼首席運營官羅伯特·邁克爾表示：“在我們前Humira增長平台的出色表現的推動下，第一季度的業績遠超出了我們的預期。”
The immunology portfolio generated $5.37 billion in sales, down 3.9% on a reported basis or 3.1% on an operational basis, due to Humira biosimilar competition.
由於Humira生物仿製藥的競爭，免疫學產品組合創造了53.7億美元的銷售額，按報告計算下降了3.9％，運營方面下降了3.1％。
Humira revenues were $2.27 billion (down 35.9%), Skyrizi sales reached $2.01 billion (up 47.6%), and Rinvoq revenues were $1.09 billion (up 59.3%).
Humira的收入爲22.7億美元（下降35.9％），Skyrizi的銷售額達到20.1億美元（增長47.6％），Rinvoq的收入爲10.9億美元（增長59.3％）。
Related: AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study.
相關： 在正面交鋒的研究中，艾伯維的皮炎藥物顯示出 “優於” 賽諾菲/Regeneron的Dupixent。
Last month, AbbVie agreed to acquire Landos Biopharma Inc (NASDAQ:LABP) for $20.42 per share, or approximately $137.5 million, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.
上個月，艾伯維同意以每股20.42美元，合約1.375億美元的價格收購蘭多斯生物製藥公司（納斯達克股票代碼：LABP），外加每股一項或有價值的權利，價值最高爲11.14美元，約合7,500萬美元。
Oncology product sales were $1.54 billion, up 9% or 9.8% on an operational basis.
腫瘤產品銷售額爲15.4億美元，按運營水平增長9％，增長9.8％。
Imbruvica revenues were $838 million (down 4.5%), Venclexta sales increased 14.2% to $614 million, and Elahere net revenues were $64 million, reflecting a partial quarter of sales based on February 12, 2024, close date of the ImmunoGen acquisition.
Imbruvica的收入爲8.38億美元（下降4.5％），Venclexta的銷售額增長了14.2％，至6.14億美元，Elahere的淨收入爲6400萬美元，反映了基於2024年2月12日，即ImmunoGen收購截止日期的部分銷售額。
Neuroscience revenues reached $1.97 billion, up 15.9% on a reported basis or 16% on an operational basis.
神經科學收入達到19.7億美元，按報告計算增長15.9％，運營收入增長16％。
Botox Therapeutic sales were $748 million, up 4.1%. Aesthetics portfolio sales reached $1.25 billion, down 4%. Global Botox Cosmetic revenues were $633 million, down 3.9%.
肉毒桿菌毒素治療的銷售額爲7.48億美元，增長4.1％。美學投資組合銷售額達到12.5億美元，下降4％。全球肉毒桿菌毒素化妝品收入爲6.33億美元，下降3.9％。
Guidance: AbbVie raised its 2024 adjusted EPS guidance from $10.97-$11.17 to $11.13-$11.33, which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter of 2024, versus consensus of $11.12.
指導方針：艾伯維將其2024年調整後的每股收益預期從10.97美元上調至11.13美元至11.33美元，其中包括與收購的知識產權研發相關的每股0.08美元的不利影響，以及2024年第一季度產生的里程碑支出，而市場預期爲11.12美元。
Price Action: ABBV shares are down 3.41% at $161.58 at the last check Friday.
價格走勢：週五最後一次支票時，ABBV股價下跌3.41％，至161.58美元。
Photo via Company
照片來自公司
譯文內容由第三人軟體翻譯。